Concepts (277)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Surgery, Plastic | 21 | 2023 | 111 | 9.400 |
Why?
|
| Mammaplasty | 9 | 2023 | 53 | 4.490 |
Why?
|
| Surgical Flaps | 6 | 2022 | 203 | 2.550 |
Why?
|
| Surgeons | 7 | 2022 | 259 | 2.100 |
Why?
|
| Internship and Residency | 8 | 2022 | 1176 | 2.010 |
Why?
|
| Breast Implantation | 4 | 2024 | 9 | 1.490 |
Why?
|
| Student Run Clinic | 2 | 2021 | 3 | 1.410 |
Why?
|
| Cosmetic Techniques | 2 | 2021 | 11 | 1.390 |
Why?
|
| Free Tissue Flaps | 2 | 2022 | 51 | 1.230 |
Why?
|
| Perforator Flap | 3 | 2023 | 9 | 1.200 |
Why?
|
| Nipples | 2 | 2020 | 6 | 1.200 |
Why?
|
| Informed Consent | 2 | 2020 | 334 | 1.080 |
Why?
|
| Relative Value Scales | 2 | 2022 | 12 | 1.000 |
Why?
|
| Pain, Postoperative | 2 | 2020 | 265 | 0.920 |
Why?
|
| Rhinoplasty | 2 | 2023 | 44 | 0.920 |
Why?
|
| Licensure, Medical | 2 | 2021 | 24 | 0.890 |
Why?
|
| Journal Impact Factor | 2 | 2021 | 22 | 0.880 |
Why?
|
| Abdominoplasty | 1 | 2022 | 5 | 0.820 |
Why?
|
| Benchmarking | 2 | 2021 | 134 | 0.820 |
Why?
|
| Mandibular Fractures | 1 | 2022 | 7 | 0.780 |
Why?
|
| Seroma | 2 | 2024 | 9 | 0.780 |
Why?
|
| Clinical Coding | 1 | 2022 | 13 | 0.780 |
Why?
|
| Employee Performance Appraisal | 1 | 2022 | 12 | 0.770 |
Why?
|
| Nose Deformities, Acquired | 1 | 2021 | 12 | 0.770 |
Why?
|
| Acellular Dermis | 2 | 2019 | 7 | 0.760 |
Why?
|
| Physician Executives | 1 | 2022 | 40 | 0.760 |
Why?
|
| Reimbursement Mechanisms | 1 | 2022 | 36 | 0.760 |
Why?
|
| Inventions | 1 | 2021 | 17 | 0.750 |
Why?
|
| Embolism, Fat | 1 | 2021 | 6 | 0.740 |
Why?
|
| Biomedical Technology | 1 | 2021 | 36 | 0.730 |
Why?
|
| Thoracotomy | 1 | 2022 | 111 | 0.730 |
Why?
|
| Commerce | 1 | 2021 | 50 | 0.720 |
Why?
|
| Personnel Selection | 1 | 2022 | 61 | 0.720 |
Why?
|
| Raynaud Disease | 1 | 2020 | 4 | 0.720 |
Why?
|
| Transplant Donor Site | 1 | 2020 | 5 | 0.720 |
Why?
|
| Academic Performance | 1 | 2020 | 18 | 0.710 |
Why?
|
| Job Application | 1 | 2020 | 18 | 0.700 |
Why?
|
| Research Personnel | 1 | 2022 | 117 | 0.700 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2020 | 40 | 0.700 |
Why?
|
| Humans | 57 | 2024 | 124610 | 0.680 |
Why?
|
| Conflict of Interest | 2 | 2022 | 67 | 0.680 |
Why?
|
| Ownership | 1 | 2020 | 33 | 0.660 |
Why?
|
| Professional Role | 1 | 2020 | 58 | 0.660 |
Why?
|
| Disclosure | 2 | 2021 | 148 | 0.650 |
Why?
|
| Postoperative Complications | 3 | 2024 | 3065 | 0.650 |
Why?
|
| Confidentiality | 1 | 2020 | 99 | 0.640 |
Why?
|
| Photography | 1 | 2020 | 95 | 0.640 |
Why?
|
| Infection Control | 1 | 2020 | 155 | 0.630 |
Why?
|
| Surgical Mesh | 1 | 2019 | 61 | 0.610 |
Why?
|
| Simulation Training | 1 | 2020 | 139 | 0.590 |
Why?
|
| Breast Implants | 4 | 2024 | 29 | 0.580 |
Why?
|
| Faculty, Medical | 1 | 2020 | 264 | 0.560 |
Why?
|
| Biomedical Research | 2 | 2023 | 516 | 0.550 |
Why?
|
| Artificial Intelligence | 1 | 2020 | 243 | 0.550 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 437 | 0.540 |
Why?
|
| Betacoronavirus | 1 | 2020 | 287 | 0.530 |
Why?
|
| Robotic Surgical Procedures | 1 | 2020 | 213 | 0.530 |
Why?
|
| Spinal Fusion | 3 | 2021 | 114 | 0.500 |
Why?
|
| Breast Neoplasms | 5 | 2024 | 2498 | 0.500 |
Why?
|
| Muscle, Skeletal | 1 | 2022 | 947 | 0.500 |
Why?
|
| Breast | 4 | 2024 | 214 | 0.490 |
Why?
|
| Fibrosis | 2 | 2014 | 431 | 0.490 |
Why?
|
| Antigens, CD | 2 | 2014 | 420 | 0.480 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 358 | 0.470 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 372 | 0.470 |
Why?
|
| United States | 12 | 2024 | 10889 | 0.460 |
Why?
|
| Microsurgery | 1 | 2015 | 68 | 0.460 |
Why?
|
| Telemedicine | 1 | 2020 | 436 | 0.450 |
Why?
|
| Monitoring, Intraoperative | 1 | 2015 | 128 | 0.450 |
Why?
|
| Decision Making | 2 | 2020 | 655 | 0.450 |
Why?
|
| Neoplasm Proteins | 2 | 2014 | 669 | 0.410 |
Why?
|
| Neuromuscular Agents | 1 | 2013 | 67 | 0.410 |
Why?
|
| Pandemics | 1 | 2020 | 1099 | 0.410 |
Why?
|
| Hypoxia | 1 | 2014 | 248 | 0.400 |
Why?
|
| Transforming Growth Factor beta | 2 | 2014 | 457 | 0.400 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 293 | 0.380 |
Why?
|
| Transplantation, Autologous | 4 | 2021 | 298 | 0.370 |
Why?
|
| Burnout, Professional | 3 | 2021 | 117 | 0.360 |
Why?
|
| Botulinum Toxins, Type A | 1 | 2013 | 167 | 0.360 |
Why?
|
| Operative Time | 2 | 2022 | 171 | 0.360 |
Why?
|
| Databases, Factual | 3 | 2024 | 1179 | 0.350 |
Why?
|
| Patient Protection and Affordable Care Act | 2 | 2021 | 64 | 0.320 |
Why?
|
| Retrospective Studies | 8 | 2023 | 16316 | 0.270 |
Why?
|
| Treatment Outcome | 7 | 2024 | 12324 | 0.260 |
Why?
|
| Physician-Patient Relations | 2 | 2020 | 429 | 0.260 |
Why?
|
| Wound Healing | 3 | 2014 | 457 | 0.240 |
Why?
|
| Thigh | 2 | 2023 | 51 | 0.230 |
Why?
|
| Female | 17 | 2024 | 66492 | 0.230 |
Why?
|
| Nose | 2 | 2023 | 93 | 0.230 |
Why?
|
| Esthetics | 3 | 2024 | 37 | 0.230 |
Why?
|
| Single-Cell Analysis | 2 | 2024 | 275 | 0.220 |
Why?
|
| Aneuploidy | 1 | 2024 | 152 | 0.220 |
Why?
|
| Gracilis Muscle | 1 | 2023 | 3 | 0.210 |
Why?
|
| Epithelial Cells | 2 | 2024 | 909 | 0.210 |
Why?
|
| Body Contouring | 1 | 2022 | 1 | 0.210 |
Why?
|
| Cell Lineage | 1 | 2024 | 338 | 0.210 |
Why?
|
| Epigastric Arteries | 1 | 2022 | 7 | 0.210 |
Why?
|
| Umbilicus | 1 | 2022 | 13 | 0.200 |
Why?
|
| Hypertrophy | 1 | 2022 | 102 | 0.200 |
Why?
|
| Mastectomy | 2 | 2020 | 64 | 0.200 |
Why?
|
| Open Access Publishing | 1 | 2022 | 2 | 0.200 |
Why?
|
| Scleroderma, Systemic | 2 | 2014 | 120 | 0.200 |
Why?
|
| Contracts | 1 | 2022 | 9 | 0.200 |
Why?
|
| Negotiating | 1 | 2022 | 11 | 0.200 |
Why?
|
| Implant Capsular Contracture | 1 | 2021 | 1 | 0.190 |
Why?
|
| Prophylactic Surgical Procedures | 1 | 2021 | 4 | 0.190 |
Why?
|
| Buttocks | 1 | 2021 | 6 | 0.190 |
Why?
|
| Equipment and Supplies | 1 | 2021 | 24 | 0.190 |
Why?
|
| Private Practice | 1 | 2021 | 22 | 0.190 |
Why?
|
| Fee-for-Service Plans | 1 | 2021 | 18 | 0.190 |
Why?
|
| Prone Position | 1 | 2021 | 31 | 0.190 |
Why?
|
| Facial Injuries | 1 | 2021 | 22 | 0.180 |
Why?
|
| Autografts | 1 | 2021 | 27 | 0.180 |
Why?
|
| Kyphosis | 1 | 2021 | 22 | 0.180 |
Why?
|
| Bibliometrics | 1 | 2021 | 31 | 0.180 |
Why?
|
| Superficial Back Muscles | 1 | 2020 | 2 | 0.180 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2021 | 46 | 0.180 |
Why?
|
| Spinal Diseases | 1 | 2021 | 45 | 0.180 |
Why?
|
| Patient Positioning | 1 | 2021 | 54 | 0.180 |
Why?
|
| Costs and Cost Analysis | 1 | 2021 | 164 | 0.180 |
Why?
|
| Pressure Ulcer | 1 | 2021 | 74 | 0.180 |
Why?
|
| Bariatric Surgery | 1 | 2022 | 119 | 0.180 |
Why?
|
| Hospitals, County | 1 | 2020 | 23 | 0.180 |
Why?
|
| Intersectoral Collaboration | 1 | 2020 | 18 | 0.180 |
Why?
|
| Surgical Wound | 1 | 2020 | 24 | 0.170 |
Why?
|
| Mastectomy, Subcutaneous | 1 | 2020 | 2 | 0.170 |
Why?
|
| Morphine | 1 | 2020 | 90 | 0.170 |
Why?
|
| Femoral Artery | 1 | 2021 | 194 | 0.170 |
Why?
|
| Necrosis | 1 | 2020 | 208 | 0.170 |
Why?
|
| Hospitals, Teaching | 1 | 2020 | 105 | 0.170 |
Why?
|
| Obesity, Morbid | 1 | 2022 | 187 | 0.170 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2020 | 19 | 0.170 |
Why?
|
| Oncologists | 1 | 2020 | 29 | 0.170 |
Why?
|
| Publications | 1 | 2020 | 33 | 0.170 |
Why?
|
| Marketing of Health Services | 1 | 2020 | 25 | 0.170 |
Why?
|
| Publishing | 1 | 2021 | 109 | 0.170 |
Why?
|
| Gene Expression Profiling | 2 | 2024 | 1702 | 0.170 |
Why?
|
| Patients | 1 | 2020 | 118 | 0.170 |
Why?
|
| Device Removal | 1 | 2021 | 221 | 0.160 |
Why?
|
| Surgical Wound Infection | 1 | 2022 | 260 | 0.160 |
Why?
|
| DNA Copy Number Variations | 1 | 2024 | 949 | 0.160 |
Why?
|
| Reoperation | 1 | 2022 | 832 | 0.160 |
Why?
|
| Elective Surgical Procedures | 1 | 2020 | 159 | 0.160 |
Why?
|
| Periodicals as Topic | 1 | 2022 | 198 | 0.160 |
Why?
|
| Pain Measurement | 1 | 2020 | 357 | 0.160 |
Why?
|
| Pain Management | 1 | 2020 | 179 | 0.150 |
Why?
|
| Hospitals, Veterans | 1 | 2020 | 359 | 0.150 |
Why?
|
| Educational Measurement | 1 | 2021 | 324 | 0.150 |
Why?
|
| Adipose Tissue | 1 | 2021 | 462 | 0.150 |
Why?
|
| Bone Transplantation | 3 | 2021 | 49 | 0.140 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 416 | 0.130 |
Why?
|
| Skin, Artificial | 1 | 2016 | 7 | 0.130 |
Why?
|
| Vascular Surgical Procedures | 1 | 2021 | 577 | 0.130 |
Why?
|
| Tissue Expansion | 1 | 2016 | 14 | 0.130 |
Why?
|
| Clinical Competence | 2 | 2021 | 998 | 0.130 |
Why?
|
| Patient Satisfaction | 1 | 2019 | 475 | 0.130 |
Why?
|
| Hemipelvectomy | 1 | 2014 | 2 | 0.120 |
Why?
|
| Erythema | 1 | 2015 | 24 | 0.120 |
Why?
|
| Length of Stay | 1 | 2020 | 1310 | 0.120 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2014 | 30 | 0.120 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2014 | 96 | 0.110 |
Why?
|
| Transplantation, Homologous | 1 | 2016 | 662 | 0.110 |
Why?
|
| Tissue Expansion Devices | 1 | 2013 | 11 | 0.110 |
Why?
|
| Graft Survival | 1 | 2016 | 536 | 0.110 |
Why?
|
| Melanoma | 1 | 2020 | 834 | 0.110 |
Why?
|
| Dermis | 1 | 2013 | 24 | 0.110 |
Why?
|
| Cicatrix | 1 | 2014 | 123 | 0.100 |
Why?
|
| Skin Neoplasms | 1 | 2020 | 808 | 0.100 |
Why?
|
| Complement C5 | 1 | 2012 | 7 | 0.100 |
Why?
|
| Bleomycin | 1 | 2013 | 150 | 0.100 |
Why?
|
| Adult | 6 | 2024 | 29437 | 0.100 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2013 | 126 | 0.100 |
Why?
|
| Sarcoma | 1 | 2014 | 183 | 0.100 |
Why?
|
| Graft Rejection | 1 | 2016 | 590 | 0.100 |
Why?
|
| Skin | 2 | 2012 | 520 | 0.100 |
Why?
|
| Complement C3 | 1 | 2011 | 48 | 0.090 |
Why?
|
| Mice, Transgenic | 2 | 2014 | 2393 | 0.090 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2011 | 51 | 0.090 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 5145 | 0.090 |
Why?
|
| Collagen Type I | 1 | 2011 | 112 | 0.090 |
Why?
|
| Drug Carriers | 1 | 2011 | 100 | 0.090 |
Why?
|
| Oxygen | 1 | 2014 | 553 | 0.090 |
Why?
|
| Accidental Falls | 1 | 2011 | 103 | 0.090 |
Why?
|
| Prospective Studies | 1 | 2020 | 6135 | 0.080 |
Why?
|
| Time Factors | 1 | 2020 | 6293 | 0.080 |
Why?
|
| Founder Effect | 1 | 2009 | 32 | 0.080 |
Why?
|
| Fractures, Bone | 1 | 2011 | 187 | 0.080 |
Why?
|
| Cause of Death | 1 | 2011 | 473 | 0.080 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2009 | 61 | 0.080 |
Why?
|
| Risk Assessment | 2 | 2016 | 3445 | 0.080 |
Why?
|
| Middle Aged | 3 | 2024 | 26713 | 0.070 |
Why?
|
| Fibronectins | 3 | 2013 | 104 | 0.070 |
Why?
|
| Male | 8 | 2021 | 61198 | 0.070 |
Why?
|
| Exons | 1 | 2009 | 796 | 0.070 |
Why?
|
| Hospital Mortality | 1 | 2011 | 1021 | 0.070 |
Why?
|
| Education, Medical, Graduate | 2 | 2021 | 517 | 0.060 |
Why?
|
| Brain Injuries | 1 | 2011 | 765 | 0.060 |
Why?
|
| Risk Factors | 1 | 2019 | 10269 | 0.060 |
Why?
|
| Clone Cells | 1 | 2024 | 166 | 0.060 |
Why?
|
| Nasal Septum | 1 | 2023 | 17 | 0.050 |
Why?
|
| Silicones | 1 | 2022 | 36 | 0.050 |
Why?
|
| Immunity | 1 | 2023 | 191 | 0.050 |
Why?
|
| Consumer Behavior | 1 | 2022 | 39 | 0.050 |
Why?
|
| Industry | 1 | 2022 | 29 | 0.050 |
Why?
|
| Administration, Topical | 2 | 2012 | 141 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2022 | 149 | 0.050 |
Why?
|
| Cost Savings | 1 | 2022 | 71 | 0.050 |
Why?
|
| Dentition | 1 | 2021 | 5 | 0.050 |
Why?
|
| Mammography | 1 | 2022 | 114 | 0.050 |
Why?
|
| Operating Rooms | 1 | 2022 | 69 | 0.050 |
Why?
|
| Self Concept | 1 | 2022 | 155 | 0.050 |
Why?
|
| Prosthesis Failure | 1 | 2022 | 158 | 0.050 |
Why?
|
| Collagen | 2 | 2013 | 315 | 0.050 |
Why?
|
| Scapula | 1 | 2021 | 12 | 0.050 |
Why?
|
| Ilium | 1 | 2021 | 23 | 0.050 |
Why?
|
| Chromatin | 1 | 2024 | 551 | 0.050 |
Why?
|
| Employment | 1 | 2021 | 68 | 0.050 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2023 | 170 | 0.050 |
Why?
|
| Job Satisfaction | 1 | 2021 | 79 | 0.050 |
Why?
|
| Cadaver | 1 | 2021 | 129 | 0.040 |
Why?
|
| Anastomosis, Surgical | 1 | 2021 | 173 | 0.040 |
Why?
|
| Accreditation | 1 | 2021 | 88 | 0.040 |
Why?
|
| Ribs | 1 | 2021 | 52 | 0.040 |
Why?
|
| Lumbar Vertebrae | 1 | 2021 | 113 | 0.040 |
Why?
|
| Animals | 4 | 2014 | 34087 | 0.040 |
Why?
|
| Spine | 1 | 2021 | 142 | 0.040 |
Why?
|
| Mice | 2 | 2014 | 17639 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2023 | 521 | 0.040 |
Why?
|
| Workload | 1 | 2020 | 145 | 0.040 |
Why?
|
| Pain | 1 | 2022 | 454 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2024 | 882 | 0.040 |
Why?
|
| Neurosurgical Procedures | 1 | 2022 | 304 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2012 | 1231 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2024 | 3040 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 460 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2021 | 371 | 0.040 |
Why?
|
| Age Factors | 1 | 2024 | 2818 | 0.040 |
Why?
|
| Aged | 3 | 2024 | 19702 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2022 | 639 | 0.030 |
Why?
|
| Rats | 2 | 2012 | 3677 | 0.030 |
Why?
|
| Genomics | 1 | 2023 | 1503 | 0.030 |
Why?
|
| Fibula | 1 | 2014 | 20 | 0.030 |
Why?
|
| Incidence | 1 | 2021 | 3138 | 0.030 |
Why?
|
| Cross-Linking Reagents | 1 | 2013 | 55 | 0.030 |
Why?
|
| Quality of Life | 1 | 2022 | 1916 | 0.030 |
Why?
|
| GPI-Linked Proteins | 1 | 2013 | 100 | 0.030 |
Why?
|
| Re-Epithelialization | 1 | 2012 | 11 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 3423 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 3693 | 0.030 |
Why?
|
| Capillary Permeability | 1 | 2012 | 75 | 0.020 |
Why?
|
| Syndrome | 1 | 2015 | 1119 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 2013 | 233 | 0.020 |
Why?
|
| Ontario | 1 | 2011 | 64 | 0.020 |
Why?
|
| Injury Severity Score | 1 | 2011 | 227 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2011 | 302 | 0.020 |
Why?
|
| Age Distribution | 1 | 2011 | 414 | 0.020 |
Why?
|
| Geriatric Assessment | 1 | 2011 | 174 | 0.020 |
Why?
|
| Trauma Centers | 1 | 2011 | 179 | 0.020 |
Why?
|
| Young Adult | 1 | 2024 | 9013 | 0.020 |
Why?
|
| Quebec | 1 | 2009 | 5 | 0.020 |
Why?
|
| Blotting, Southern | 1 | 2009 | 215 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 1102 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2011 | 428 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2009 | 461 | 0.020 |
Why?
|
| DNA Primers | 1 | 2009 | 657 | 0.020 |
Why?
|
| Cell Movement | 1 | 2011 | 836 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2011 | 1495 | 0.020 |
Why?
|
| Haplotypes | 1 | 2009 | 521 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2011 | 882 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 1690 | 0.020 |
Why?
|
| Registries | 1 | 2011 | 1424 | 0.010 |
Why?
|
| Prevalence | 1 | 2011 | 2445 | 0.010 |
Why?
|
| Base Sequence | 1 | 2009 | 3090 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2013 | 4352 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2011 | 4795 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2013 | 4505 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2011 | 6533 | 0.010 |
Why?
|